The ␦-opioid receptor (DOR) can undergo proteolytic down-regulation by endocytosis of receptors followed by sorting of internalized receptors to lysosomes. Although phosphorylation of the receptor is thought to play an important role in controlling receptor downregulation, previous studies disagree on whether phosphorylation is actually required for the agonist-induced endocytosis of opioid receptors. Furthermore, no previous studies have determined whether phosphorylation is required for subsequent sorting of internalized receptors to lysosomes. We have addressed these questions by examining the endocytic trafficking of a series of mutant versions of DOR expressed in stably transfected HEK 293 cells. Our results confirm that phosphorylation is not required for agonist-induced endocytosis of truncated mutant receptors that lack the distal carboxylterminal cytoplasmic domain containing sites of regulatory phosphorylation. However, phosphorylation is required for endocytosis of full-length receptors. Mutation of all serine/threonine residues located in the distal carboxyl-terminal tail domain of the full-length receptor to alanine creates functional mutant receptors that exhibit no detectable agonist-induced endocytosis. Substitution of these residues with aspartate restores the ability of mutant receptors to undergo agonist-induced endocytosis. Studies using green fluorescent proteintagged versions of arrestin-3 suggest that the distal tail domain, when not phosphorylated, inhibits receptormediated recruitment of ␤-arrestins to the plasma membrane. Biochemical and radioligand binding studies indicate that, after endocytosis occurs, phosphorylationdefective mutant receptors traffic to lysosomes with similar kinetics as wild type receptors. We conclude that phosphorylation controls endocytic trafficking of opioid receptors primarily by regulating a "brake" mechanism that prevents endocytosis of full-length receptors in the absence of phosphorylation. After endocytosis occurs, subsequent steps of membrane trafficking mediating sorting and transport to lysosomes do not require receptor phosphorylation.
G protein-coupled receptors (GPCRs) 1 are regulated by multiple mechanisms. Many GPCRs undergo a process of rapid desensitization within seconds to minutes after ligand-induced activation, mediated by ligand-dependent phosphorylation of receptors followed by the association of phosphorylated receptors with arrestins. This cascade of events causes functional uncoupling of receptors from heterotrimeric G proteins and promotes the rapid endocytosis of receptors by clathrin-coated pits (reviewed in Refs. [1] [2] [3] . Endocytosis of GPCRs by clathrincoated pits can modulate receptor activity in two ways that have opposing effects on receptor-mediated signaling. First, endocytosis can target receptors to a rapid recycling pathway that contributes to functional resensitization of signal transduction by returning dephosphorylated receptors to the plasma membrane. Second, endocytosed receptors can undergo a distinct, slower process of proteolytic down-regulation that causes a prolonged attenuation of signal transduction by reducing the total number of receptors present in cells (4, 5) . Down-regulation of GPCRs is of great interest because it is associated with certain pathological states and can be influenced by clinically relevant drugs (6) . Multiple mechanisms can contribute to GPCR down-regulation (4, 7, 8) , including specific sorting of internalized receptors to lysosomes (7) .
Opioid receptors compose a subfamily of GPCRs that undergo desensitization, endocytosis, and down-regulation following ligand-induced activation (9 -11) . Rapid desensitization and endocytosis are promoted by receptor phosphorylation (12) (13) (14) (15) (16) . Previous studies suggest that phosphorylation may also be required for down-regulation of opioid receptors (17) (18) (19) . However, this may not be true in all cases (20) , and no previous studies have defined the role of phosphorylation in specific mechanisms of receptor down-regulation. In particular, it is not known whether phosphorylation is required for lysosomal proteolysis of opioid receptors.
A recent study (7) has established that ␦-opioid receptors are targeted to lysosomes by a highly selective molecular sorting operation that occurs within several minutes after endocytosis. Although phosphorylation is well known to promote the endocytosis and inhibit the recycling of many GPCRs (reviewed in Refs. 1-3), including opioid receptors (15, 16) , it is not known at which step(s) of receptor down-regulation phosphorylation is specifically required.
This question has been difficult to address because, in many systems, manipulations or mutations that block phosphoryla-tion of receptors also strongly inhibit endocytosis by clathrincoated pits, thereby precluding study of later step(s) in the pathway mediating receptor trafficking to lysosomes. In the present study, we have circumvented this complication by examining a previously described truncated mutant ␦-opioid receptor (DOR344T) that is unable to undergo any detectable constitutive or ligand-induced phosphorylation yet, when expressed in HEK293 cells, exhibits rapid agonist-induced endocytosis by clathrin-coated pits (21) . In addition, we have generated several other mutant full-length opioid receptors that have alterations in their trafficking properties. Our results support the hypothesis that the distal portion of the carboxylterminal cytoplasmic domain functions as an endocytic "brake" mechanism that is released by phosphorylation. This mechanism appears to play an important role in controlling lysosomal proteolysis of full-length opioid receptors primarily by limiting the rate at which activated receptors can enter the endocytic pathway. Hence, phosphorylation does play an important role in controlling down-regulation of the full-length ␦-opioid receptor by modulating its rapid endocytosis. Nevertheless, phosphorylation is not essential for rapid endocytosis of a truncated mutant receptor nor is it required for efficient sorting of truncated or full-length receptors to lysosomes after endocytosis has occurred.
EXPERIMENTAL PROCEDURES

Cell Culture and cDNA Constructs
Human embryonic kidney cells (HEK293) cells were maintained and passaged in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (University of California, San Francisco Cell Culture Facility). A stable cell line expressing FLAG-tagged DOR (DOR5) was generated as described previously (7) . The previously described truncated mutant DOR (DOR344T) cell line was constructed by engineering a stop codon following residue 344 in the coding sequence of the FLAG-tagged murine DOR and introducing the cDNA into HEK293 cells via calcium phosphate precipitation and G418 selection (21) . HAtagged versions of DOR and DOR344T were also generated in a pCDNA3.1 backbone for this study. Stable cell lines of these constructs were generated by introducing them into HEK293 cells via calcium phosphate precipitation and Zeocin selection. The receptor point mutants DOR5A and DOR3D were engineered by site-directed mutagenesis of the HA-tagged wild type DOR using the Quick Change sitedirected mutagenesis protocol (Stratagene). Stable cell lines of these constructs were also generated by introducing them into HEK293 cells via calcium phosphate precipitation and Zeocin selection. At least two stable cell lines were generated and analyzed for each receptor. Double stable cell lines expressing GFP-arrestin and receptor were generated by cotransfection with both constructs using calcium phosphate precipitation followed by selection with both G418 and Zeocin. The Arg 169 3 Glu ␤-arrestin-EE was generated using the Quick-Change site-directed mutagenesis protocol (Stratagene) of a construct described previously (16) . Relative receptor expression levels were quantified using immunofluorescence microscopy and/or radioligand binding using [ 3 H]diprenorphine (see below for methods).
Radioligand Binding
Agonist-induced down-regulation of receptors was assayed in intact cells using a method described previously (39) . Briefly, monolayers of cells expressing FLAG-tagged full-length DOR (DOR5) and FLAGtagged truncated mutant DOR (DOR344T) were incubated for 3 h at 37°C in the absence or presence of 10 M DADLE (Research Biochemicals). To ensure a saturating concentration of peptide agonist over the incubation period, monolayers incubated with DADLE were supplemented with fresh peptide every hour during the incubation. At the end of the incubation, cells were lifted with PBS supplemented with EDTA and washed four times by centrifugation with 10 ml of warm (37°C) PBS. Then cells were washed once by centrifugation in 10 ml of KrebsRinger HEPES buffer (KHRB, 110 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 , 25 mM glucose, 55 mM sucrose, 10 mM HEPES, pH 7.3). Radioligand binding was carried out in 120 l of KHRB containing equal amounts of washed cells (50 -100 g of protein) with 2 nM [
3 H]diprenorphine. Incubations were carried out for 30 min at room temperature and terminated by vacuum filtration through glass fiber filters (Packard Instruments) and repeated washes with ice-cold Tris-buffered saline, pH 7.4. Bound radioactivity was determined by scintillation counting (Scintiverse, Fisher) using a Beckman LS 6500 instrument. For all determinations, bound radioligand represented Յ10% of total radioligand present in the incubation, and nonspecific binding (defined by assays conducted in the presence of 10 M naloxone) was Յ10% of counts isolated on glass fiber filters. All assays were conducted in triplicate with similar results. Results are expressed as mean picomoles of radioligand specifically bound per mg of cells assayed (protein concentration was determined by the method of Bradford et al. (40) using reagents from Bio-Rad).
Analysis of Receptor Phosphorylation
Receptor phosphorylation was assessed as described previously (41) . Briefly, cells stably expressing receptor were grown in Dulbecco's modified Eagle's medium with 10% serum to 80% confluency and then starved for 1 h in phosphate-free media. Cells were metabolically labeled for 3 h with 0.25 mCi/ml [ 32 P]orthophosphate (Amersham Pharmacia Biotech) and then treated with the indicated agonist or incubated in the absence of agonist for 30 min. Cells were washed in cold PBS and lysed (25 mM HEPES, pH 7.4, 50 mM NaCl, 0.1% Triton X-100, 1 mM CaCl 2 , 50 mM NaF, 80 mM ␤-glycerol phosphate, 0.1 mM sodium orthovanadate, 1 g/ml leupeptin, 1 g/ml pepstatin A, 2 g/ml aprotinin, and 2 g/ml phenylmethylsulfonyl fluoride). Receptors were immunoprecipitated, deglycosylated, resolved by SDS-PAGE, and the gel exposed to film.
␤-Arrestin Recruitment
Cells stably expressing both receptor and GFP-tagged ␤-arrestin-2 (a gift from Marc Caron) were plated to coverslips and allowed to recover for 2 days. Cells were fed HA-11 anti-HA antibody (Covance) or M1 anti-FLAG antibody (Sigma), as appropriate, for 30 min (1:1000, 4 g/ml) to label epitope-tagged receptors present in the plasma membrane and then treated with the indicated agonist for 10 min. Cells were fixed and permeabilized as described previously (16) and then receptors were stained with Texas Red-conjugated donkey anti-mouse antibody (1:500, Jackson ImmunoResearch). GFP-tagged ␤-arrestin-2 and antibody-labeled receptor were visualized by conventional epifluorescence microscopy using a Nikon 60ϫ NA1.4 objective and standard filter sets (Chroma Optical) that allowed dual label imaging with no detectable bleed through between channels. For the ␤-arrestin-1 Arg 169 3 Glu experiments, cells stably expressing DOR5A and transiently transfected with an EE-tagged version of ␤-arrestin-1 Arg 169 3 Glu were fed anti-HA antibody 12CA5 for 30 min, treated with agonist, fixed, and permeabilized as above. Cells were incubated with anti-EE antibodies (Covance), to recognize the overexpressed mutant ␤-arrestin-1 (1:1000), and a rabbit anti-IgG2b linker (Jackson ImmunoResearch 1:500). Cells were then stained with IgG 1 -selective fluorescein isothiocyanate antimouse (Roche Molecular Biochemicals) and Texas Red anti-rabbit antibodies both at 1:500. Epifluorescence microscopy was performed using a Nikon 60ϫ NA1.4 objective and standard filter sets (Chroma Optical) that allowed dual label imaging with no detectable bleed through between channels.
Membrane Adenylyl Cyclase Assays
Membrane Preparation-Cells were grown to 80% confluency and pretreated with 2 M DADLE or left untreated. Cells were lifted in PBS with 0.04% EDTA, washed 4 times in 15 ml of PBS to remove residual agonist, and were then resuspended in 1 ml of ice-cold buffer of 25 mM MgCl 2 , 75 mM Tris⅐HCl, 2 mM EDTA, pH 7.5, and pelleted at 2000 ϫ g for 5 min. The pellet was resuspended with a glass potter in the same buffer and immediately assayed.
Adenylyl Cyclase Assay-Membranes were incubated in 30 mM Tris⅐HCl, 1 mM EDTA, 50 M GTP, 0.1 mM cAMP, 40 M ATP, 10 mM creatine phosphate, 200 units/ml creatine phosphokinase, 1 Ci of [␣-
32 P]ATP, and 1 M forskolin with or without etorphine for 30 min at 37°C. Reactions were stopped by addition of HCl to 1 M and applied to acidic alumina spin columns (Pierce). Columns were washed and eluted according to the manufacturer's instructions, and eluate was counted by using a Beckman LS 6500 scintillation counter.
Immunoblotting
Monolayers of cells expressing FLAG-tagged DOR (DOR5) or truncated mutant DOR (DOR344T) were incubated in the absence or presence of 10 M etorphine. Monolayers were preincubated for 1 h at 37°C with 100 g/ml leupeptin (Calbiochem), 200 M chloroquine (Sigma), or 50 mM ammonium chloride (Sigma) before agonist addition, and these reagents were present in the medium during agonist incubation. Equal amounts of cell lysate (prepared by extracting monolayers with 0.1% Triton X-100 (Sigma)) were resolved by SDS-PAGE, transferred to nitrocellulose membranes, and blotted for FLAG-tagged receptor using M1 monoclonal antibody (Sigma) followed by detection using horseradish peroxidase-conjugated goat anti-mouse antibody (Jackson ImmunoResearch) and ECL (Amersham Pharmacia Biotech).
Biochemical Analysis of Receptor Endocytosis Using Cleavable Biotin: Biotin Protection
Cells were grown to 80% confluency in 10-cm plates, washed with PBS, and then treated with 3 g/ml disulfide-cleavable biotin (Pierce) in PBS at 4°C for 30 min. Cells were then washed in PBS and placed in pre-warmed media for 15 min, prior to treatment with specified ligands for varying times. Concurrent with ligand treatment, 100% and strip plates remained at 4°C. Following ligand treatment, plates were washed in PBS, and the remaining cell surface biotinylated receptors were stripped in 50 mM glutathione, 0.3 M NaCl, 75 mM NaOH, and 1% fetal bovine serum at 4°C for 30 min for all ligand-treated plates as well as strip plate. Cells were extracted in 0.1% Triton X-100, 150 mM NaCl, 25 mM KCl, and 10 mM Tris⅐HCl, pH 7.4, and cellular debris was removed by centrifugation at 10,000 ϫ g for 10 min at 4°C. Lysates were immunoprecipitated with anti-FLAG M2 (Covance), rabbit antimouse linker antibody (Jackson ImmunoResearch), and protein A-Sepharose (Amersham Pharmacia Biotech) overnight. Immunoprecipitates were washed 5ϫ and incubated with PNGase F (New England Biolabs) for 2 h. Samples were then denatured in SDS sample buffer with no reducing agent and resolved by SDS-PAGE and transferred to nitrocellulose, and biotinylated proteins were visualized with Vectastain ABC immunoperoxidase reagent (Vector Laboratories) and developed with ECL reagents (Amersham Pharmacia Biotech).
Biochemical Analysis of Receptor Degradation Using Noncleavable Biotin: Biotin Degradation
Proteolytic degradation of surface-biotinylated receptors was estimated using a protocol described previously (27) . Briefly, stably transfected cells expressing receptor were surface-biotinylated by incubation at 4°C with 30 mg/ml sulfo-NHS-biotin (Pierce), rinsed with Trisbuffered saline to quench the biotinylation reaction, warmed to 37°C, and incubated under various conditions as described in the text and then chilled on ice to stop further membrane trafficking. Cells were extracted and receptor immunoprecipitates were prepared, and biotinylated receptor protein recovered in immunoprecipitates was detected by streptavidin overlay. Receptor degradation was indicated by a loss of biotinylated protein recovered in immunoprecipitates and was quantified by densitometric scanning of streptavidin overlays exposed in the linear range. Samples representing equal numbers of cells were loaded in each lane.
Biochemical Analysis of Post-endocytic Receptor Degradation Using Cleavable Biotin: Biotin Protection/Degradation
Cells stably expressing epitope-tagged receptor were biotinylated at 4°C with 30 mg/ml sulfo-NHS-SS-biotin (Pierce) rinsed with Tris-buffered saline to quench the biotinylation reaction, warmed to 37°C, and incubated with or without 10 M etorphine for 30 min or 3 h. The remaining cell surface biotin was cleaved with stripping buffer containing membrane-impermeant reducing agent (50 mM glutathione, 0.3 M NaCl, 75 mM NaOH, and 1% fetal bovine serum). Stripping was quenched, and cells were lysed in lysis buffer (0.1% Triton X-100, 150 mM NaCl, 25 mM KCl, 10 mM Tris⅐Cl, pH 7.4, 1 g/ml leupeptin, 1 g/ml pepstatin A, 2 g/ml aprotinin, and 2 g/ml phenylmethylsulfonyl fluoride). As controls, cells were biotinylated, quenched, and lysed (100%) or biotinylated, stripped, quenched, and lysed (strip). Receptors were immunoprecipitated using antibodies to the epitope tag (either M1 (Sigma) or HA-11 (Covance)), deglycosylated using PNGase F (New England Biolabs), and resolved by SDS-PAGE, and "protected" biotinylated receptors were visualized by streptavidin overlay (Vector Laboratories) and ECL (Amersham Pharmacia Biotech). In this way, this assay follows the fate specifically of endocytosed receptors.
RESULTS
A truncated, mutant ␦-opioid receptor (DOR344T) missing the distal portion of the cytoplasmic tail containing all known sites of regulatory phosphorylation has been shown previously to undergo agonist-induced endocytosis in HEK293 cells (21) (Fig. 1B) despite its lack of phosphorylation (21) (Fig. 1A) . To examine whether phosphorylation was required for endocytosis of full-length receptors, we created a full-length mutant version of DOR in which all serine and threonine residues located in the carboxyl-terminal cytoplasmic tail were mutated to alanine (DOR5A mutant receptor). These include Thr-358 and Ser-363 shown to be primary sites of DOR phosphorylation (22, 23) . Consistent with these previous studies, the DOR5A full-length mutant receptor exhibited no detectable phosphorylation in intact cells, like the DOR344T truncated mutant receptor described previously (Fig. 1A) .
Visualization of receptors by fluorescence microscopy indicated that the DOR5A mutant receptor localized primarily in the plasma membrane of cells incubated in the absence of agonist (Fig. 1B, upper panels) . However, in contrast to the pronounced agonist-induced internalization of the phosphorylation-defective DOR344T-truncated mutant receptor (Fig. 1B,  lower panels) , fluorescence microscopy indicated that the DOR5A mutant receptor failed to exhibit detectable internalization even after 30 min of continuous exposure to a saturating concentration of agonist (Fig. 1B, lower panel) . Quantification of receptor internalization using a biochemical assay described previously (16) , biotin protection, that measures internalization of biotinylated receptors by inaccessibility to a membrane-impermeant reducing agent indicated that internalization of the DOR5A mutant receptor was inhibited Ͼ90% relative to that of wild type DOR or DOR344T observed under similar conditions (Fig. 1C) . Thus, the distal portion of the carboxyl-terminal cytoplasmic tail of DOR, although not necessary for agonist-induced endocytosis of truncated mutant receptors, strongly inhibits endocytosis of full-length receptors when mutated to prevent phosphorylation.
We next examined whether phosphorylation might regulate the inhibitory function of the distal tail domain on receptor endocytosis. To accomplish this, the phosphorylation-defective DOR5A construct was modified by replacing residues in positions 358, 361, and 363 with aspartate (DOR3D mutant receptor). These positions correspond to a distal serine/threonine cluster containing primary site(s) of phosphorylation in wild type DOR (22, 23) . The DOR3D mutant receptor was localized predominantly in the plasma membrane and exhibited minimal internalization in the absence of agonist, as visualized by fluorescence microscopy (Fig. 1B) and confirmed by the biotin protection assay (Fig. 1C) . However, in contrast to the DOR5A mutant receptor, the DOR3D mutant receptor exhibited readily detectable internalization after addition of agonist (Fig. 1, B and C) even though this receptor was not detectably phosphorylated (Fig. 1A) . These observations suggest that phosphorylation of the distal portion of the carboxyl-terminal cytoplasmic domain of DOR, although not sufficient to promote endocytosis of full-length receptors in the absence of agonist, is necessary to relieve the inhibitory effect of this cytoplasmic domain on endocytosis of receptors after agonist-induced activation.
Phosphorylation stimulates endocytosis of many GPCRs, including opioid receptors, by promoting receptor interaction with ␤-arrestins (15, 16) . This suggests that the distal cytoplasmic tail of DOR, when not phosphorylated, might mediate its inhibitory effects on receptor endocytosis by preventing membrane recruitment of ␤-arrestins. To test this possibility, we utilized a method described previously (24) to detect visually membrane recruitment of GFP-tagged ␤-arrestin-2 (arrestin 3) by fluorescence microscopy. Double stable cell lines were generated that expressed both receptor and GFP-arrestin. Consistent with previous studies (24) , agonist-induced activation of the wild type DOR strongly promoted recruitment of ␤-arrestin to numerous receptor-containing puncta associated with the plasma membrane ( Fig. 2A, left panels) . In contrast, activation
FIG. 2. Arrestin recruitment and desensitization by DOR and DOR mutants.
A, cells stably expressing GFP-arrestin and either DOR, DOR5A, or DOR3D were fed antibody to the aminoterminal epitope on the receptor, treated with agonist (10 M etorphine) for 10 min, fixed, permeabilized, and stained with Texas Red-labeled secondary antibody. Receptor and arrestin localization were examined by conventional fluorescence microscopy. Both DOR and DOR3D showed robust arrestin recruitment, whereas the non-internalizing DOR5A showed no detectable arrestin recruitment. B, cells stably expressing DOR, DOR5A, or DOR3D were treated with 2 M DADLE for 10 min or left untreated. Cells were washed of residual agonist; membranes were prepared, and receptor activity was assessed by membrane adenylyl cyclase assay as described under "Experimental
Procedures." DOR, DOR5A, and DOR3D all inhibited adenylyl cyclase activity with DOR3D showing small but significantly reduced activity compared with DOR (unpaired t test, p ϭ 0.03). Both DOR and DOR3D showed significant rapid desensitization following the 10-min pretreatment (unpaired t test, p ϭ 0.001 for DOR and p ϭ 0.002 for DOR3D). DOR5A showed no significant desensitization under the same conditions (unpaired t test, p Ͼ 0.5).
of the DOR5A mutant receptor, expressed at similar levels, failed to mediate any detectable redistribution of ␤-arrestin from the cytoplasm under the same conditions ( Fig. 2A, middle  panels) . Significantly, the DOR3D mutant receptor, like wild type DOR, mediated pronounced agonist-induced redistribution of GFP-tagged ␤-arrestin-2 to the plasma membrane ( Fig.  2A, right panels) . Taken together, these results suggest that a distal portion of the DOR cytoplasmic tail, when not phosphorylated, inhibits endocytosis of full-length receptors by preventing receptor interaction with ␤-arrestins. Phosphorylation of this domain (as in wild type DOR), or acidic substitution to mimic the effects of phosphorylation (as in DOR3D), appears to release this endocytic brake by allowing agonist-activated receptors to recruit ␤-arrestins to the plasma membrane.
We next examined the functional consequences associated with the differences in ␤-arrestin recruitment and endocytosis of DOR, DOR5A, and DOR3D. All three receptors mediated agonist-dependent inhibition of forskolin-stimulated membrane adenylyl cyclase activity measured in membranes prepared from stably transfected cells (Fig. 2B) . DOR3D showed somewhat reduced inhibition of adenylyl cyclase, even when expressed at levels closely similar to those of the other receptors and exposed to a saturating concentration of agonist. This observation suggests that the acidic mutations may cause reduced receptor coupling to adenylyl cyclase by mimicking the phosphorylated state. To examine desensitization, cells were pretreated for 10 min at 37°C with the peptide agonist DADLE (2 M), washed on ice to remove residual agonist, and lysed, and membrane adenylyl cyclase activity was assessed following agonist rechallenge in the isolated membrane fractions. DORexpressing cells showed substantial desensitization consistent with the significant ␤-arrestin recruitment we observed at this time point in these cells. Consistent with their inability to recruit ␤-arrestin, DOR5A-expressing cells showed no detectable desensitization under these conditions. Importantly, DOR3D-expressing cells exhibited pronounced desensitization following agonist pretreatment. These results demonstrate that both the DOR5A and DOR3D mutant receptors are competent for signaling to the adenylyl cyclase pathway, support previous studies (24) indicating that ␤-arrestin recruitment, visualized by fluorescence microscopy, is a reliable indicator of rapid desensitization, and suggest that the ability of the dephosphorylated DOR tail domain to inhibit ␤-arrestin recruitment is functionally relevant to the regulation of receptormediated signal transduction in these cells.
There are at least two mechanisms by which the phosphorylation state of the receptor tail could affect recruitment of ␤-arrestins. First, the unphosphorylated tail could contribute to a conformation of the receptor that is itself unable to interact with ␤-arrestins with high affinity, as shown previously in studies of other GPCRs (25) . Second, the unphosphorylated tail could interfere with the ability of ␤-arrestins to access the activated receptor by interacting with another cytoplasmic protein. To distinguish between these possibilities, we utilized a mutant form of arrestin, ␤-arrestin-1 (arrestin 2) Arg 169 3 Glu, that has been established previously to interact with unphosphorylated receptors both in reconstituted systems (25) and Xenopus oocytes (26) . We then examined whether ␤-arrestin-1 Arg 169 3 Glu could facilitate endocytosis of a non-phosphorylatable ␦-opioid receptor (DOR5A, Fig. 1A) . The mutant Arg 169 3 Glu arrestin was generated from a previously described EE-tagged version of ␤-arrestin-1 (16) and transiently transfected into our cell line stably expressing the DOR5A receptor. Even in cells that highly overexpressed this mutant ␤-arrestin, DOR5A mutant receptors failed to exhibit significant agonistinduced internalization (Fig. 3, upper panel) . Furthermore, activated DOR5A receptors did not cause detectable recruitment of ␤-arrestin-1 Arg 169 3 Glu to the plasma membrane (Fig. 3, lower panel) . Hence, despite its ability to interact with non-phosphorylated receptors in vitro (25) and in Xenopus oocytes (26) , this mutant arrestin did not interact detectably with non-phosphorylated, full-length receptors in HEK293 cells. These observations confirm that the cytoplasmic tail of DOR inhibits arrestin interaction when not phosphorylated, and they suggest that the distal portion of the DOR tail mediates a phosphorylation-releasable brake mechanism that inhibits arrestin interaction with activated receptors in mammalian cells but not in Xenopus oocytes (26) . Although we cannot exclude the possibility that the tail of the full-length DOR is in a different conformation in oocytes than it is in mammalian cells, we favor the hypothesis that, in mammalian cells, the unphosphorylated receptor interacts with a distinct brake protein that inhibits arrestin interaction and thus endocytosis. When the tail of the receptor is truncated, however, this brake protein can no longer bind the receptor tail, as its binding site has been removed. In this way, we can explain the apparent paradox that phosphorylation of a truncated receptor is not required for endocytosis, but phosphorylation is required for endocytosis of a full-length receptor.
We next addressed whether phosphorylation was necessary for trafficking of opioid receptors to lysosomes after endocytosis. We first utilized radioligand binding to compare the ability of full-length DOR and the phosphorylation-defective DOR344T mutant receptor to undergo agonist-induced downregulation. Consistent with previous studies (7), we found ϳ50% down-regulation in the total number of full-length DORbinding sites within 3 h after the addition of peptide (DADLE) or alkaloid (etorphine) agonist to the culture medium (Fig. 4A) . The DOR344T mutant receptor, expressed at comparable levels, exhibited a similar amount of down-regulation under the same conditions (Fig. 4A) . Saturation binding analysis con-
FIG. 3. Recruitment of phosphorylation-independent arrestin
Arg 169 3 Glu (R169E). Cells stably expressing DOR5A were transiently transfected with an EE-tagged version of a mutant form of arrestin, Arg 169 3 Glu, that has been reported to interact with opioid receptors in a phosphorylation-independent manner (26) . Cells were fed antibody to the amino-terminal epitope on the receptor, treated with agonist (10 M etorphine) for 10 min, fixed, permeabilized, and incubated with antibody directed against the EE tag. Cells were then stained with fluorescein isothiocyanate and Texas Red-labeled secondary antibodies. There was no difference in the endocytic behavior of cells expressing endogenous levels of arrestin and adjacent cells overexpressing arrestin Arg 169 3 Glu (upper panel). DOR5A receptors also failed to recruit this mutant arrestin (lower panel).
firmed that this decrease in radioligand binding reflected reduced receptor number (Fig. 4B) . We used immunoblotting to determine whether down-regulation of the DOR344T mutant receptor observed under these conditions was mediated by agonist-induced proteolysis, as is true for wild type DOR expressed in these cells. DOR344T mutant receptors, like fulllength DOR (7), exhibited extensive proteolysis within 3 h after the addition of either alkaloid or peptide agonist to the culture medium (Fig. 4C, left panel) . Proteolysis of the DOR344T mutant receptor, like that of the full-length DOR, was sensitive to inhibitors of lysosomal proteolysis (Fig. 5C, right panel) . This observation indicates that the phosphorylation-defective DOR344T mutant receptor, like the wild type DOR, undergoes extensive agonist-induced proteolysis in lysosomes.
Both of the previous assays, radioligand binding and immunoblot, assess the stability of the entire pool of receptor protein.
To examine specifically the fate of only the receptors present initially in the plasma membrane, we utilized an assay described previously involving surface biotinylation (27) . Little or no proteolysis of cell surface receptors was observed in the absence of agonist, as indicated by the uniformly high recovery of biotinylated receptors in immunoprecipitates (Fig. 4D) . In contrast, biotinylated receptors were nearly undetectable in immunoprecipitates prepared from cells after incubation with agonist (10 M etorphine) for 3 h, indicating that the entire pool of DOR344T present initially in the plasma membrane can be extensively proteolyzed within this time period (Fig. 4D) . Quantification of multiple experiments by densitometric scanning confirmed that biotinylated DOR344T mutant receptors were proteolyzed to a similar extent as full-length DOR (Fig.  4E) . Furthermore, examination of the time course of agonistinduced proteolysis indicated that DOR and DOR344T were proteolyzed with closely similar kinetics (Fig. 4F) .
We next examined the fate of agonist-activated, phosphorylation-defective, full-length receptors present on the cell surface using the biotin degradation assay (27) . Consistent with their Each data point represents the mean of triplicate determinations. C, the effect of leupeptin (leu), ammonium chloride (AC), or chloroquine (cq) on proteolysis of DOR344T was determined by preincubation of cells with inhibitors for 1 h at 37°C and then treatment with 10 M etorphine for 3 h in the continued presence of inhibitors. D, degradation of surface-expressed receptors was analyzed using the biotin degradation assay as described under "Experimental Procedures." E and F, biotinylated receptor protein for DOR and DOR344T was quantified by densitometric scanning of streptavidin overlays from multiple biotin degradation experiments (27) failure to undergo agonist-induced endocytosis, surface-biotinylated DOR5A mutant receptors exhibited no detectable proteolysis after exposure of stably transfected cells to a saturating concentration of agonist for 3 h (Fig. 5A, upper panel) . In contrast, DOR3D mutant receptors exhibited substantial proteolysis when analyzed under similar conditions (Fig. 5A, lower  panel) . However, surface-biotinylated DOR3D mutant receptors were proteolyzed to a somewhat reduced extent relative to wild type DOR examined at the same time points (see Fig. 4D ). It was possible that the reduced extent of DOR3D proteolysis was primarily a consequence of a partial inhibition of receptor endocytosis caused by this mutation, thus reducing the number of internalized receptors that can be subsequently sorted to lysosomes. Alternatively, it was possible that this observation could reflect a specific defect in the sorting of DOR3D mutant receptors to lysosomes after endocytosis. To distinguish between these possibilities, we used a modified version of the biotinylation method that we term biotin protection/degradation, which allows the specific evaluation of the post-endocytic fate of receptors. Briefly, cells expressing wild type DOR, DOR344T, DOR5A, or DOR3D were biotinylated using a disulfide-linked ("cleavable") biotin. Cells were then incubated with agonist for 30 min or 3 h or left untreated. At the end of the respective incubations, biotinylated receptors present in the plasma membrane (either not internalized or recycled) were then "stripped" by exposing intact cells to membraneimpermeant reducing agent, and the recovery of "protected" biotinylated receptors (representing only those receptors present in the endocytic pathway) was assayed in immunoprecipitates. This method specifically follows the fate of receptors that were initially on the cell surface and were then endocytosed, and thereby it specifically assesses the post-endocytic fate of receptors. These results indicated that the internalized pool of DOR3D receptors, like DOR344T truncated mutant receptors, was extensively proteolyzed within 3 h after initial endocytosis (Fig. 5B) .
These results emphasize the importance of distinguishing between mutations that inhibit receptor down-regulation by inhibiting receptor endocytosis and mutations that inhibit down-regulation by affecting post-endocytic trafficking of receptors. Specifically, whereas mutations in DOR3D appeared to partially inhibit down-regulation of the receptor (Fig. 5A compare with Fig. 4D ), these mutations did not, in fact, inhibit the post-endocytic sorting operation that mediates targeting of the receptors to lysosomes (Fig. 5B) . Taken together, our results indicate that phosphorylation is not required for sorting of truncated (DOR344T) or full-length (DOR3D) mutant receptors to lysosomes after endocytosis. In addition, because the acidic mutations in DOR3D are not reversible like phosphorylation events are, these results also suggest that dephosphorylation of the receptor is not required for post-endocytic sorting of the receptors to lysosomes.
DISCUSSION
The present results clarify the role of phosphorylation in controlling agonist-induced endocytic membrane trafficking of DOR, thus providing insight into differences in the conclusions of previous studies regarding whether or not phosphorylation is required for regulated endocytosis (10, 21) and down-regulation of mutant opioid receptors (12, 17, 18, 22, 23, 28) . In particular, our results suggest that the distal portion of the carboxyl-terminal cytoplasmic domain of DOR is not required for regulated endocytosis but functions as an endocytic brake that is "released" by phosphorylation in order to allow endocytosis of full-length receptors to occur. At first glance, this hypothesis is reminiscent of a previous study suggesting that the cytoplasmic tail of the -opioid receptor inhibits endocytosis (29) . However, in this case, truncation of the corresponding tail domain caused constitutive endocytosis of receptors (i.e. endocytosis in the absence of agonist), and it was not determined whether this inhibitory effect was regulated by phosphorylation. The present studies, using GFP-tagged versions of ␤-arrestin-2, suggest that the endocytic inhibitory effect of the cytoplasmic tail of DOR is associated with a blockade of receptor-mediated recruitment of ␤-arrestin to the plasma membrane. In addition, our studies of post-endocytic trafficking of DOR344T mutant receptors indicate that, after endocytosis occurs, subsequent steps mediating trafficking of opioid receptors to lysosomes do not require phosphorylation of the receptor protein.
The close association observed in this study between the ability of mutant receptors to undergo agonist-induced endocytosis and proteolysis suggests that a major point at which phosphorylation regulates lysosomal proteolysis of full-length opioid receptors is by controlling the rate of initial endocytosis. However, because of the essentially complete blockade of DOR5A endocytosis, we are unable to exclude a possible additional role of the dephosphorylated tail in inhibiting later step(s) mediating trafficking of full-length (but not truncated) receptors to lysosomes. Such an additional role has been suggested previously in controlling post-endocytic trafficking of the full-length ␤ 2 -adrenergic receptor (30) and V2 vasopressin receptor (31, 32) , and is consistent with previous kinetic and mutational (22, 28) studies of opioid receptor internalization and down-regulation. Future studies will be necessary to address this possibility and to elucidate the biochemical mechanism mediating phosphorylation-independent sorting of internalized opioid receptors to lysosomes. In addition, because membrane trafficking to lysosomes is only one mechanism that can mediate proteolytic down-regulation of opioid receptors (33, 34) , it will be interesting to determine in future studies whether distinct mechanisms of proteolysis differ in their regulation by receptor phosphorylation. Clarification of this issue may provide insight into the functional basis for the conservation in mammalian cells of multiple mechanisms mediating regulated proteolysis of GPCRs.
We conclude that phosphorylation is not required for the specific sorting mechanism mediating proteolytic down-regulation of opioid receptors. Although phosphorylation has been FIG. 5 . Agonist-induced proteolysis of DOR point mutants. Proteolysis of surface-expressed receptors was analyzed using the biotin degradation assay as described under "Experimental Procedures." A, cells stably expressing DOR5A or DOR3D were biotinylated and treated with 10 M etorphine for 3 h or left untreated. DOR5A receptors were very stable (upper panel), presumably due to their failure to endocytose. DOR3D receptors were somewhat more stable than DORs (compare lower panel to Fig. 4D ) but significantly more unstable than DOR5A receptors (upper panel). B, biotin protection/degradation as described under "Experimental Procedures" was used to follow selectively the post-endocytic fate of receptors. Internalized DOR3D receptors were as unstable as analogously treated DORs and DOR344T. DOR5A mutants failed to internalize. Blots are representative of at least 2 independent experiments.
shown previously to play an important role in regulating rapid endocytosis and recycling of GPCRs (see for example Refs. 35 and 36) , to our knowledge the present study is the first to establish that phosphorylation is not necessary for the efficient sorting of internalized receptors to lysosomes. In addition our data suggest that the tail of the receptor not only acts as a facilitator of arrestin recruitment and endocytosis when it is phosphorylated but that it antagonizes these processes when it is not. These observations may provide new insight into how certain agonists and receptor mutations, as well as different arrestin and GRK mutations, might differentially affect rapid internalization and slower down-regulation of opioid receptors (10, 37) and certain other GPCRs that are internalized by clathrin-coated pits (e.g. Ref. 38) . Taken together, these observations suggest the existence of phosphorylation-independent mechanisms controlling GPCR sorting in the endocytic pathway. Elucidating these mechanisms and their physiological consequences is an important goal for future studies.
